Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Part of University of Adelaide, Adelaide Research & Innovation Pty Ltd. is an Australian company located in Adelaide. The firm provides analytical research services. Robert Chalmers is the current CEO of the firm.

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Yamasa Corp. manufactures and supplies soy sauce and seasonings. It processes and supplies soy sauce, seasonings, sauces, dips, and flavorings. The firm also develops pharmaceuticals and biochemicals. The company was founded in 1645 and is headquartered in Choshi, Japan.

Nestec SA, a subsidiary of Nestlé SA, is a Swiss company located in Vevey. The firm manufactures nutrition food products.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Yellowfin is a global Business Intelligence and analytics software vendor with a suite of world-class products powered by automation. Yellowfin is continually recognized as an innovator and is No. 1 in Embedded BI by BARC. In February 2021 Yellowfin was recognized as a Visionary in the Gartner Magic Quadrant for Analytics and Business Intelligence Platforms for the second consecutive year. Yellowfin is proud to be at the forefront of innovation in Augmented Analytics. More than 29,000 organizations and over 3 million end-users across 75 countries use Yellowfin every day. For more information, please visit us at www.yellowfinbi.com

Morinaga Milk Industry Co., Ltd. engages in the production and distribution of dairy products. Its operations are carried out through the following segments: Food Products and Others. The Food Products segment engages in the production and sale of milk, dairy-based beverages, yogurt, desserts, condensed milk, powdered milk, butter, cheese, ice cream, non-dairy beverages (juice, tea, coffee), and clinical liquid diets. The Others segment provides the real estate leasing services. It also engages in the manufacture and sale of animal feeds; design and construction of plant equipment. The company was founded on September 1, 1917 and is headquartered in Tokyo, Japan.

Jinheshiye is a company dedicated to serving healthy living and advanced manufacturing,specializing in chemical, biological &new materials. It is a major producer of sweeteners acesulfame,sucralose and maltol.the company's main business is food activities and interdients,edible and daily flavours and fragrances,pharmaceutical and pesticide intermediates,functional chemicals and bulk chemicals, mainly serving food and beverages,daily consumption ,medical health,agricultural environmental protection and advanced manufacturing.

Xinghua Green Biological Products Co., Ltd., established on 2005-09-02, Business scope includes import and export operations,Production,sell plant extracts(steviol glycoside,plant polysaccharide,Phlorizin,Phloretin,shikimic acid,mast yellow,Geniposide,gardenia blue,gardenia red,gardenia green,Proantho Cyanidins,Capsanthin etc.);Production of condiments,other food,food additives(Product category limit<food production license>Approved scope),Sell ​​the company's own products;Procurement and sales of plant extract raw materials,semi-finished product,finished product;stevia planting,Purchase and sale of dried stevia leaves;Feed additives,Production of food fermented products,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sinochem Health Industry Development Co., Ltd. is a company headquartered in Qingdao, China and ultimately controlled by the Government of China, focused on chemicals and allied products.